Company Profiles

driven by the PitchBook Platform

Altimmune

Description

Developer of vaccines and other biological products to address market and public health needs. The company uses proprietary technology for non-invasive delivery to the nasal passages or to the skin. It develops vaccines for influenza, anthrax, avian influenza, tetanus and alzheimer.

1997

Founded

PRIVATE

Status

11-50

Employees

Reverse Merger

Latest Deal Type

$22.5M

Total Amount Raised

8

Investors

Description

Developer of vaccines and other biological products to address market and public health needs. The company uses proprietary technology for non-invasive delivery to the nasal passages or to the skin. It develops vaccines for influenza, anthrax, avian influenza, tetanus and alzheimer.

Website:

www.altimmune.com

Formerly Known As

Vaxin Pharmaceuticals, ImmuneFocus

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

19 Firstfield Road Gaithersburg, MD 20878United States +1 (240) 654-1450
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Altimmune's full profile, request a free trial.

Altimmune Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Altimmune Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Altimmune Investors (8)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
AnC Bio GroupCorporationMinority000 0000000 0000
Bonaventure CapitalVenture CapitalMinority000 0000000 0000
Greer Capital AdvisorsVenture CapitalMinority000 0000000 0000
HealthCapVenture CapitalMinority000 0000000 0000
KolmarCorporationMinority000 0000000 0000
AnC Bio Group Corporation
Bonaventure Capital Venture Capital
Greer Capital Advisors Venture Capital
HealthCap Venture Capital
Kolmar Corporation

Altimmune Executive Team (5)

NameTitleBoard
Seat
Contact
Info
Bill EnrightChief Executive Officer, President and Board Member
Elizabeth CzerepakChief Financial Officer
Bertrand GeorgesChief Technology Officer
Scot Roberts Ph.DChief Scientific Officer
Sybil TaskerSenior Vice President, Clinical, Research & Development
Bill Enright Chief Executive Officer, President and Board Member
Elizabeth Czerepak Chief Financial Officer
Bertrand Georges Chief Technology Officer
Scot Roberts Ph.D Chief Scientific Officer
Sybil Tasker Senior Vice President, Clinical, Research & Development

Altimmune Board Members (6)

NameRepresentingRoleSinceContact
Info
Christine Brennan Ph.DNovartis Venture FundsPrincipal000 0000
David Drutz MDSelfChairman000 0000
Klaus Schafer MDSelfBoard Member000 0000
Marten Steen Ph.DHealthCapPartner000 0000
Philippe Pouletty MDTruffle CapitalCo-Founder, Owner & Managing Director, Life Sciences000 0000
Christine Brennan Ph.D Principal Novartis Venture Funds
David Drutz MD Chairman Self
Klaus Schafer MD Board Member Self
Marten Steen Ph.D Partner HealthCap
Philippe Pouletty MD Co-Founder, Owner & Managing Director, Life Sciences Truffle Capital
Request full access to PitchBook